Drugs for Obstructive Airway Diseases

DrugDrug NameDrug Indication
DB00180FlunisolideFor the maintenance treatment of asthma as a prophylactic therapy.
DB00221IsoetarineFor the treatment of asthma, wheezing, and chronic asthmatic bronchitis.
DB00277TheophyllineFor the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
DB00471MontelukastMontelukast is indicated for: (a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304]; (b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and (c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307]. Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331] Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328] Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an 'as required' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]
DB00549ZafirlukastFor the prophylaxis and chronic treatment of asthma.
DB00620TriamcinoloneFor the treatment of perennial and seasonal allergic rhinitis.
DB00651DyphyllineFor relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.
DB00668EpinephrineEpinephrine injection is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Injectable epinephrine is intended for immediate/urgent administration in patients, who are found to be at increased risk for anaphylaxis, including individuals with a history of anaphylaxis. Selection of the appropriate dosage strength is determined according to body weight [FDA label]. Epinephrine's cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes but is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock [F1247]. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics [F1247]. In addition to the above, epinephrine is used as an over the counter (OTC) agent for the intermittent symptoms of asthma, such as wheezing, tightness of chest and shortness of breath [F2131]. It is also used for the maintenance of mydriasis during intraocular surgery [L4825].
DB00816OrciprenalineFor the treatment of bronchospasm, chronic bronchitis, asthma, and emphysema.
DB00871TerbutalineFor the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial.
DB00901BitolterolUsed to dilate air passages in the lungs that have become narrowed as a result of disease or inflammation. It is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB00938SalmeterolFor the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB00983FormoterolFor use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator. Not indicated for asthma that can be successfully managed with occasional use of an inhaled, short-acting beta2-adrenergic agonist. Also used for the prevention of exercise-induced bronchospasm, as well as long-term treatment of bronchospasm associated with COPD.
DB01001SalbutamolSalbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm [FDA Label, F3265, F3268].
DB01003Cromoglicic acidFor the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.
DB01025AmlexanoxUsed as a paste in the mouth to treat aphthous ulcers (canker sores).
DB01064IsoprenalineFor the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis
DB01223AminophyllineFor the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
DB01291PirbuterolFor the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible bronchospasm including asthma.
DB01303OxtriphyllineUsed to treat the symptoms of asthma, bronchitis, COPD, and emphysema.
DB01366ProcaterolFor the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB01407ClenbuterolUsed as a bronchodilator in the treatment of asthma patients.
DB01408BambuterolFor the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
DB01409TiotropiumUsed in the management of chronic obstructive pulmonary disease (COPD).
DB01411PranlukastUsed as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
DB01656RoflumilastRoflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
DB05039IndacaterolFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
DB05266IbudilastFor the treatment of multiple sclerosis, asthma, and cerebrovascular disease.
DB06602ReslizumabIndicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
DB06739SeratrodastNot Available
DB08897AclidiniumAclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
DB08906Fluticasone furoateFluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
DB08957HexoprenalineNot Available
DB08979FenspirideNot Available
DB09076UmeclidiniumIndicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
DB09080OlodaterolOlodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
DB09082VilanterolVilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta and in combination with umeclidinium bromide as Anoro Ellipta. Approved by the FDA in 2013, use of Breo Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
DB09273DoxofyllineIndicated for the treatment of chronic obstructive pulmonary disease (COPD), bronchial asthma and pulmonary disease with spastic bronchial component.
DB12086OxitropiumNot Available
DB12248TulobuterolNot Available
DB12846ReproterolNot Available
DB13203BamifyllineNot Available
DB13395EprozinolNot Available
DB13449ProxyphyllineNot Available
DB13559RimiterolNot Available
DB13573AcefyllineNot Available
DB13592EtamiphyllineNot Available
DB13624MethoxyphenamineNot Available
DB13625CarbuterolNot Available
DB13692TretoquinolNot Available
DB13812BufyllineNot Available
DB14018BromotheophyllineBromotheophylline is used as a diuretic and also, in combination with [DB00316], it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.[L2737]
DB00201CaffeineFor management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.
DB00332IpratropiumInhaled ipratropium is indicated in combination with inhaled beta-agonist systemic corticosteroids for the management of severe exacerbations of asthma flares requiring treatment.[A176939] Asthma exacerbations are characterized by a progressive increase in one or more of asthma symptoms accompanied by a decrease in expiratory flow.[L5900] As a single agent, ipratropium was indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for patients 5 years or older. It does not alleviate nasal congestion nor sneezing.[FDA label] Rhinorrhea refers to recurrent or chronic watery nasal discharge. This condition is debilitating and its pathogenesis and etiology is complex and not very well understood presenting very substantial cost burden.[L5903] Additionally, ipratropium is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.[FDA label] The chronic obstructive pulmonary disease includes a large number of conditions characterized by breathlessness. As this includes several conditions, the etiology, symptoms, and treatments are diverse.[L5906] Ipratropium has also been studied to be used for the treatment of sialorrhea.[A176942] Sialorrhea is a common symptom that accompanies different neurologic conditions and it is characterized by drooling or excessive salivation.[A176963]
DB00394Beclomethasone dipropionateUsed in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
DB00443BetamethasoneNot Available
DB00716NedocromilFor the treatment of mild to moderate asthma
DB00764MometasoneThe inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
DB00806PentoxifyllineFor the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
DB00986GlycopyrroniumFor use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. Also used to treat chronic obstructive pulmonary disease (COPD).
DB01222BudesonideThe oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.
DB01288FenoterolFenoterol is used for the treatment of asthma.
DB01364EphedrineEphedrine commonly used as a stimulant, appetite suppressant, concentration aid, decongestant, and to treat hypotension associated with anaesthesia.
DB01410CiclesonideFor the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
DB01412Theobrominetheobromine is used as a vasodilator, a diuretic, and heart stimulant. And similar to caffeine, it may be useful in management of fatigue and orthostatic hypotension.
DB13867FluticasoneFluticasone's 2 esters are indicated as inhalers for the treatment and management of asthma by prophylaxis[FDA Label][F4364]as well as inflammatory and pruritic dermatoses[F4355]. A [DB00588] nasal spray is indicated for managing nonallergic rhinitis[F4358] while the [DB08906] nasal spray is indicated for treating season and perennial allergic rhinitis[F4361,A177130].
DB06612MepolizumabMepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history
DB06742AmbroxolAmbroxol is indicated for secretolytic therapy in bronchoplmonary diseaes with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
DB12023BenralizumabBenralizumab is indicated as a maintenance treatment of patients 12 years or older with severe asthma and an eosinophilic phenotype.[L1020] The pathology of severe asthma with eosinophilic phenotype is also denotated as TH2-high phenotype. The patients with this phenotype are characterized by the expression of IL-5 and IL-13, airway hyperresponsiveness, responsiveness to inhaled corticosteroids, high serum IgE and eosinophilia in blood and airway. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation and migration to the lungs.[A31295]
DrugDrug NameTargetType
DB00180FlunisolideCorticosteroid-binding globulincarrier
DB00180FlunisolideGlucocorticoid receptortarget
DB00180FlunisolideCytochrome P450 3A4enzyme
DB00221IsoetarineBeta-1 adrenergic receptortarget
DB00221IsoetarineBeta-2 adrenergic receptortarget
DB00277TheophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00277TheophyllineAdenosine receptor A2btarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00277TheophyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00277TheophyllineAdenosine receptor A1target
DB00277TheophyllineAdenosine receptor A2atarget
DB00277TheophyllineCytochrome P450 1A2enzyme
DB00277TheophyllineAdenosine deaminaseenzyme
DB00277TheophyllineCytochrome P450 2E1enzyme
DB00277TheophyllineCytochrome P450 3A4enzyme
DB00277TheophyllineSolute carrier family 22 member 7transporter
DB00277TheophyllineCytochrome P450 1A1enzyme
DB00277TheophyllineCytochrome P450 1B1enzyme
DB00277TheophyllineCytochrome P450 2C8enzyme
DB00277TheophyllineCytochrome P450 2D6enzyme
DB00277TheophyllineHistone deacetylase 2target
DB00277TheophyllineMinor histocompatibility antigen H13target
DB00277TheophyllineNodal modulator 1target
DB00277TheophyllinePoly [ADP-ribose] polymerase 1target
DB00277TheophyllineProtein RIC-3target
DB00277TheophyllineTubulin monoglycylase TTLL3target
DB00471MontelukastCysteinyl leukotriene receptor 1target
DB00471MontelukastArachidonate 5-lipoxygenasetarget
DB00471MontelukastCytochrome P450 3A4enzyme
DB00471MontelukastCytochrome P450 2C9enzyme
DB00471MontelukastCytochrome P450 2C8enzyme
DB00471MontelukastSolute carrier organic anion transporter family member 2B1transporter
DB00471MontelukastProstaglandin G/H synthase 1enzyme
DB00471MontelukastCytochrome P450 2A6enzyme
DB00549ZafirlukastCysteinyl leukotriene receptor 1target
DB00549ZafirlukastCytochrome P450 2C9enzyme
DB00549ZafirlukastCytochrome P450 2C8enzyme
DB00549ZafirlukastProstaglandin G/H synthase 1enzyme
DB00549ZafirlukastCytochrome P450 3A4enzyme
DB00549ZafirlukastCytochrome P450 1A2enzyme
DB00549ZafirlukastCytochrome P450 2C19enzyme
DB00549ZafirlukastCytochrome P450 2E1enzyme
DB00549ZafirlukastATP-binding cassette sub-family G member 2transporter
DB00620TriamcinoloneCorticosteroid-binding globulincarrier
DB00620TriamcinoloneGlucocorticoid receptortarget
DB00620TriamcinoloneCytochrome P450 3A4enzyme
DB00620TriamcinoloneProstaglandin G/H synthase 2enzyme
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB00651DyphyllineHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7Atarget
DB00651DyphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 7Btarget
DB00651DyphyllineAdenosine receptor A1target
DB00651DyphyllineAdenosine receptor A2atarget
DB00668EpinephrineAlpha-1A adrenergic receptortarget
DB00668EpinephrineBeta-1 adrenergic receptortarget
DB00668EpinephrineBeta-2 adrenergic receptortarget
DB00668EpinephrineSolute carrier family 22 member 2transporter
DB00668EpinephrineSolute carrier family 22 member 1transporter
DB00668EpinephrineCytochrome P450 2C9enzyme
DB00668EpinephrineCytochrome P450 3A4enzyme
DB00668EpinephrineAlpha-1B adrenergic receptortarget
DB00668EpinephrineAlpha-1D adrenergic receptortarget
DB00668EpinephrineAlpha-2A adrenergic receptortarget
DB00668EpinephrineAlpha-2B adrenergic receptortarget
DB00668EpinephrineTumor necrosis factortarget
DB00668EpinephrineCatechol O-methyltransferaseenzyme
DB00668EpinephrineMonoamine oxidaseenzyme
DB00816OrciprenalineBeta-2 adrenergic receptortarget
DB00871TerbutalineBeta-2 adrenergic receptortarget
DB00871TerbutalineBeta-3 adrenergic receptortarget
DB00871TerbutalineBeta-1 adrenergic receptortarget
DB00901BitolterolBeta-2 adrenergic receptortarget
DB00938SalmeterolBeta-2 adrenergic receptortarget
DB00938SalmeterolCytochrome P450 3A4enzyme
DB00938SalmeterolCytochrome P450 2C8enzyme
DB00938SalmeterolCytochrome P450 3A5enzyme
DB00938SalmeterolCytochrome P450 3A7enzyme
DB00938SalmeterolBeta-1 adrenergic receptortarget
DB00938SalmeterolBeta-3 adrenergic receptortarget
DB00983FormoterolBeta-2 adrenergic receptortarget
DB00983FormoterolCytochrome P450 2C19enzyme
DB00983FormoterolCytochrome P450 2C9enzyme
DB00983FormoterolCytochrome P450 2D6enzyme
DB00983FormoterolCytochrome P450 2A6enzyme
DB00983FormoterolBeta-1 adrenergic receptortarget
DB00983FormoterolBeta-3 adrenergic receptortarget
DB01001SalbutamolBeta-2 adrenergic receptortarget
DB01001SalbutamolBeta-1 adrenergic receptortarget
DB01001SalbutamolCytochrome P450 3A4enzyme
DB01001SalbutamolBeta-3 adrenergic receptortarget
DB01003Cromoglicic acidCalcium-activated potassium channel subunit alpha-1target
DB01003Cromoglicic acidProtein S100-Ptarget
DB01025AmlexanoxProtein S100-A12target
DB01025AmlexanoxProtein S100-A13target
DB01025AmlexanoxFibroblast growth factor 1target
DB01064IsoprenalineBeta-1 adrenergic receptortarget
DB01064IsoprenalineBeta-2 adrenergic receptortarget
DB01064IsoprenalinePhosphatidylinositol 3-kinase regulatory subunit alphatarget
DB01064IsoprenalineBeta-3 adrenergic receptortarget
DB01064IsoprenalineMitogen-activated protein kinase 1target
DB01064IsoprenalinePhosphatidylinositol 3-kinase regulatory subunit betatarget
DB01064IsoprenalinePhosphatidylinositol 3-kinase regulatory subunit gammatarget
DB01064IsoprenalineCytochrome P450 1A1enzyme
DB01064IsoprenalineCAMP phosphodiesterasetarget
DB01064IsoprenalineSuperoxide dismutase [Cu-Zn]target
DB01223AminophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01223AminophyllineAdenosine receptor A3target
DB01223AminophyllineAdenosine receptor A1target
DB01223AminophyllineCytochrome P450 1A2enzyme
DB01223AminophyllineCytochrome P450 2E1enzyme
DB01223AminophyllineCytochrome P450 3A4enzyme
DB01223AminophyllineHistone deacetylase 2target
DB01223AminophyllineCytochrome P450 2C19enzyme
DB01291PirbuterolBeta-2 adrenergic receptortarget
DB01291PirbuterolBeta-1 adrenergic receptortarget
DB01303OxtriphyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01303OxtriphyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01303OxtriphyllineAdenosine receptor A2atarget
DB01303OxtriphyllineAdenosine receptor A1target
DB01303OxtriphyllineCytochrome P450 1A2enzyme
DB01303OxtriphyllineSolute carrier family 22 member 7transporter
DB01303OxtriphyllineHistone deacetylase 2target
DB01366ProcaterolBeta-2 adrenergic receptortarget
DB01407ClenbuterolBeta-2 adrenergic receptortarget
DB01407ClenbuterolBeta-nerve growth factortarget
DB01407ClenbuterolTumor necrosis factortarget
DB01407ClenbuterolBeta-1 adrenergic receptortarget
DB01407ClenbuterolBeta-3 adrenergic receptortarget
DB01407ClenbuterolCytochrome P450 1A1enzyme
DB01408BambuterolBeta-2 adrenergic receptortarget
DB01409TiotropiumMuscarinic acetylcholine receptor M3target
DB01409TiotropiumCytochrome P450 2D6enzyme
DB01409TiotropiumCytochrome P450 3A4enzyme
DB01409TiotropiumMuscarinic acetylcholine receptor M1target
DB01409TiotropiumMuscarinic acetylcholine receptor M2target
DB01409TiotropiumSolute carrier family 22 member 5transporter
DB01409TiotropiumSolute carrier family 22 member 4transporter
DB01409TiotropiumMuscarinic acetylcholine receptor M4target
DB01409TiotropiumMuscarinic acetylcholine receptor M5target
DB01411PranlukastTumor necrosis factortarget
DB01411PranlukastEosinophil cationic proteintarget
DB01411PranlukastNuclear factor NF-kappa-B p105 subunittarget
DB01411PranlukastCysteinyl leukotriene receptor 1target
DB01411PranlukastCytochrome P450 3A4enzyme
DB01411PranlukastCanalicular multispecific organic anion transporter 1transporter
DB01411PranlukastCytochrome P450 2C9enzyme
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB01656RoflumilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB01656RoflumilastCytochrome P450 3A4enzyme
DB05039IndacaterolBeta-2 adrenergic receptortarget
DB05039IndacaterolCytochrome P450 3A4enzyme
DB05039IndacaterolUDP-glucuronosyltransferase 1-1enzyme
DB05039IndacaterolMultidrug resistance protein 1transporter
DB05266IbudilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB05266IbudilastcGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB05266IbudilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB05266IbudilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Ctarget
DB05266IbudilastcAMP-specific 3',5'-cyclic phosphodiesterase 4Dtarget
DB06739SeratrodastCytochrome P450 2C9enzyme
DB06739SeratrodastCytochrome P450 3A4enzyme
DB06739SeratrodastCytochrome P450 2C8enzyme
DB06739SeratrodastCytochrome P450 2C19enzyme
DB06739SeratrodastCytochrome P450 2B6enzyme
DB06739SeratrodastUDP-glucuronosyltransferase 1-9enzyme
DB06739SeratrodastProstaglandin G/H synthase 1enzyme
DB06739SeratrodastCytochrome P450 2A6enzyme
DB06739SeratrodastThromboxane A2 receptortarget
DB08897AclidiniumMuscarinic acetylcholine receptor M1target
DB08897AclidiniumMuscarinic acetylcholine receptor M2target
DB08897AclidiniumMuscarinic acetylcholine receptor M3target
DB08897AclidiniumMuscarinic acetylcholine receptor M4target
DB08897AclidiniumMuscarinic acetylcholine receptor M5target
DB08906Fluticasone furoateCytochrome P450 3A4enzyme
DB08906Fluticasone furoateGlucocorticoid receptortarget
DB08906Fluticasone furoateMultidrug resistance protein 1transporter
DB08906Fluticasone furoateCytochrome P450 2C8enzyme
DB08906Fluticasone furoateSolute carrier organic anion transporter family member 1B1transporter
DB08906Fluticasone furoateCorticosteroid-binding globulincarrier
DB08906Fluticasone furoateMultidrug resistance protein 1carrier
DB08906Fluticasone furoateSolute carrier organic anion transporter family member 1B1carrier
DB08906Fluticasone furoateCytochrome P450 3A5enzyme
DB08906Fluticasone furoateCytochrome P450 3A7enzyme
DB08906Fluticasone furoateProgesterone receptortarget
DB08906Fluticasone furoateMineralocorticoid receptortarget
DB09076UmeclidiniumMuscarinic acetylcholine receptor M1target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M2target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M3target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M4target
DB09076UmeclidiniumMuscarinic acetylcholine receptor M5target
DB09076UmeclidiniumCytochrome P450 2D6enzyme
DB09076UmeclidiniumMultidrug resistance protein 1transporter
DB09080OlodaterolBeta-2 adrenergic receptortarget
DB09080OlodaterolCytochrome P450 2C9enzyme
DB09080OlodaterolCytochrome P450 2C8enzyme
DB09082VilanterolCytochrome P450 3A4enzyme
DB09082VilanterolBeta-2 adrenergic receptortarget
DB09273DoxofyllinePhosphodiesterase 2A, cGMP-stimulatedtarget
DB09273DoxofyllineAdenosine receptor A2atarget
DB09273DoxofyllineBeta-2 adrenergic receptortarget
DB09273DoxofyllineCytochrome P450 1A2enzyme
DB12248TulobuterolBeta-2 adrenergic receptortarget
DB13203BamifyllineCytochrome P450 1A2enzyme
DB13449ProxyphyllineCytochrome P450 1A2enzyme
DB13573AcefyllineCytochrome P450 1A2enzyme
DB13592EtamiphyllineCytochrome P450 1A2enzyme
DB13812BufyllineCytochrome P450 1A2enzyme
DB14018BromotheophyllineCytochrome P450 1A2enzyme
DB00201CaffeineAdenosine receptor A1target
DB00201CaffeinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00201CaffeineAdenosine receptor A2atarget
DB00201CaffeineCytochrome P450 1A2enzyme
DB00201CaffeineRyanodine receptor 1target
DB00201CaffeineCytochrome P450 3A4enzyme
DB00201CaffeineCytochrome P450 3A5enzyme
DB00201CaffeineCytochrome P450 3A7enzyme
DB00201CaffeineMultidrug resistance protein 1transporter
DB00201CaffeineCytochrome P450 2E1enzyme
DB00201CaffeineCytochrome P450 2C8enzyme
DB00201CaffeineCytochrome P450 2C9enzyme
DB00201CaffeineCytochrome P450 1A1enzyme
DB00201CaffeineCytochrome P450 1B1enzyme
DB00201CaffeineCytochrome P450 2D6enzyme
DB00201CaffeineCyclic nucleotide phosphodiesterasetarget
DB00201CaffeineDNA-dependent protein kinase catalytic subunittarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DB00201CaffeinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformtarget
DB00201CaffeineInositol 1,4,5-trisphosphate receptortarget
DB00201CaffeineSerine-protein kinase ATMtarget
DB00332IpratropiumMuscarinic acetylcholine receptor M1target
DB00332IpratropiumMuscarinic acetylcholine receptor M2target
DB00332IpratropiumMuscarinic acetylcholine receptor M3target
DB00332IpratropiumSolute carrier family 22 member 5transporter
DB00332IpratropiumSolute carrier family 22 member 4transporter
DB00332IpratropiumSerum albumincarrier
DB00332Ipratropiumalpha1-acid glycoproteincarrier
DB00394Beclomethasone dipropionateCorticosteroid-binding globulincarrier
DB00394Beclomethasone dipropionateGlucocorticoid receptortarget
DB00394Beclomethasone dipropionateCytochrome P450 3A5enzyme
DB00394Beclomethasone dipropionateCytochrome P450 3A4enzyme
DB00443BetamethasoneGlucocorticoid receptortarget
DB00443BetamethasoneCytochrome P450 3A4enzyme
DB00443BetamethasoneMultidrug resistance protein 1transporter
DB00443BetamethasoneCytochrome P450 19A1enzyme
DB00716NedocromilCysteinyl leukotriene receptor 1target
DB00716NedocromilCysteinyl leukotriene receptor 2target
DB00716NedocromilProstaglandin D2 receptortarget
DB00716NedocromilfMet-Leu-Phe receptortarget
DB00716NedocromilHeat shock protein HSP 90-alphatarget
DB00764MometasoneGlucocorticoid receptortarget
DB00764MometasoneCytochrome P450 2C8enzyme
DB00764MometasoneProgesterone receptortarget
DB00764MometasoneCytochrome P450 3A4enzyme
DB00806PentoxifyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00806PentoxifyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00806PentoxifyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00806PentoxifyllineAdenosine receptor A1target
DB00806PentoxifyllineAdenosine receptor A2atarget
DB00806PentoxifyllineCytochrome P450 1A2enzyme
DB00986GlycopyrroniumMuscarinic acetylcholine receptor M1target
DB00986GlycopyrroniumMuscarinic acetylcholine receptor M3target
DB00986GlycopyrroniumMuscarinic acetylcholine receptor M2target
DB01222BudesonideGlucocorticoid receptortarget
DB01222BudesonideCytochrome P450 3A4enzyme
DB01222BudesonideCytochrome P450 3A5enzyme
DB01222BudesonideBile salt export pumptransporter
DB01288FenoterolBeta-2 adrenergic receptortarget
DB01288FenoterolBeta-1 adrenergic receptortarget
DB01288FenoterolBeta-3 adrenergic receptortarget
DB01364EphedrineAlpha-1A adrenergic receptortarget
DB01364EphedrineSodium-dependent noradrenaline transportertarget
DB01364EphedrineSynaptic vesicular amine transportertarget
DB01410CiclesonideCorticosteroid-binding globulincarrier
DB01410CiclesonideCytochrome P450 3A4enzyme
DB01410CiclesonideCytochrome P450 2D6enzyme
DB01410CiclesonideGlucocorticoid receptortarget
DB01410CiclesonideLiver carboxylesterase 1enzyme
DB01412TheobromineCytochrome P450 1A2enzyme
DB01412TheobromineCytochrome P450 2E1enzyme
DB01412TheobromineAdenosine receptor A1target
DB01412TheobromineAdenosine receptor A2atarget
DB01412TheobrominecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB13867FluticasoneCytochrome P450 3A4enzyme
DB13867FluticasoneCytochrome P450 2C8enzyme
DB13867FluticasoneMultidrug resistance protein 1carrier
DB13867FluticasoneSolute carrier organic anion transporter family member 1B1carrier
DB13867FluticasoneMultidrug resistance protein 1transporter
DB13867FluticasoneSolute carrier organic anion transporter family member 1B1transporter
DB13867FluticasoneGlucocorticoid receptortarget
DB13867FluticasoneCorticosteroid-binding globulincarrier
DB13867FluticasoneCytochrome P450 3A5enzyme
DB13867FluticasoneCytochrome P450 3A7enzyme
DB13867FluticasoneProgesterone receptortarget
DB13867FluticasoneCytosolic phospholipase A2target
DB13867FluticasoneMineralocorticoid receptortarget
DB06742AmbroxolCytochrome P450 3A4enzyme
DB12023BenralizumabInterleukin-5 receptor subunit alphatarget
DB12023BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget